Oncology

Metastatic Breast Cancer

Advertisement
Later-line Treatment With Antibody-Drug Conjugates for HR+/HER2- Metastatic Breast Cancer
Metastatic Breast Cancer

Later-line Treatment With Antibody-Drug Conjugates for HR+/HER2- Metastatic Breast Cancer

expert roundtables
By Joanne Mortimer, MD, FACP, FASCO; David Rimm, MD, PhD; Sagar D. Sardesai, MBBS
Expert Roundtables Podcast: Treating Patients With HR+/HER2- Metastatic Breast Cancer at Initial Diagnosis
Metastatic Breast Cancer

Expert Roundtables Podcast: Treating Patients With HR+/HER2- Metastatic Breast Cancer at Initial Diagnosis

expert roundtables
By Joanne Mortimer, MD, FACP, FASCO; David Rimm, MD, PhD; Sagar D. Sardesai, MBBS
Prediction of Response and Resistance to Antibody-Drug Conjugate Therapy for HR+/HER2- Metastatic Breast Cancer
Metastatic Breast Cancer

Prediction of Response and Resistance to Antibody-Drug Conjugate Therapy for HR+/HER2- Metastatic Breast Cancer

clinical topic updates
By David Rimm, MD, PhD
Redefining HR+ Disease and Treatment Selection in Metastatic Breast Cancer
Metastatic Breast Cancer

Redefining HR+ Disease and Treatment Selection in Metastatic Breast Cancer

clinical topic updates
By David Rimm, MD, PhD
Special Considerations in Treating Older Adults With Metastatic Breast Cancer
Metastatic Breast Cancer

Special Considerations in Treating Older Adults With Metastatic Breast Cancer

patient care perspectives
By Sagar D. Sardesai, MBBS
Load More   

Experts in Metastatic Breast Cancer

+3

Meet the Experts   

Advertisement